.png){kind=icon}
返回
Ofatumumab
.png){kind=icon}
PRE
AI
DOI：10.2165/11203850-000000000-00000.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Ofatumumab is a fully human anti-CD20 monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity in CD20-expressing B lymphocytes. Ofatumumab is highly potent in lysing B cells, and this appears to stem from its binding site on the short extracellular loop of the target CD20 protein and its slow release from the target molecule. In a pivotal, noncomparative study in patients with fludarabine- and alemtuzumab-refractory chronic lymphocytic leukaemia (CLL), ofatumumab induced objective responses in 58% (99% Cl 40, 74) of patients, which met a prespecified superiority criterion. The median duration of response was 7.1 months. The median progression-free survival was 5.7 months and the median overall survival was 13.7 months. In patients with fludarabine- and alemtuzumab-refractory CLL, infections and neutropenia were the most frequent treatment-related adverse events (all grades) that occurred during ofatumumab treatment; infections that commenced during treatment led to death in five patients (8%).
Keyword:
CHRONIC LYMPHOCYTIC-LEUKEMIA
ANTI-CD20 ANTIBODY
SINGLE-AGENT
RITUXIMAB
DIAGNOSIS
CD20
AI总结
对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
14.4
论文数:
8.4K
被引数:
2.3W
机构
引用论文
Hemodynamics and muscle sympathetic nerve activity after 8 h of sustained hypoxia in healthy humans
PREAI
分享收藏分享收藏分享收藏分享收藏The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20
OAAI
OAAI分享收藏Treatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapy.png)
LEUKEMIA
LEUKEMIAIF13.4
PREAI
分享收藏
查看更多内容